Other Information.
−Removed: Form of Convertible Promissory Note (incorporated by reference to Exhibit 4.55 to the Company’s Annual Report on Form 10-K filed on October 15, 2019).
−Removed: Form of First Convertible Redeemable Promissory Note (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on January 17, 2020).
−Removed: Form of Second Convertible Redeemable Promissory Note (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on January 17, 2020).
−Removed: Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.56 to the Company’s Annual Report on Form 10-K filed on October 15, 2019).
−Removed: Form of First Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 17, 2020).
−Removed: Form of Second Securities Purchase Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on January 17, 2020).
−Removed: Certification
−Removed: of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification
−Removed: of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification
−Removed: of the Principal Executive Officer pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
−Removed: Certification
−Removed: of the Principal Financial Officer pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
+Added: October 1, 2020, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”)
+Added: to provide certain research services to the Company.
+Added: In consideration of such services, the Company agreed to pay the University
+Added: approximately 30,000 Euros ($35,145 USD) which shall be paid in four installment payment of 5,000 Euros in November 2020, 5,000
+Added: Euros ($5,858) in March 2021, 10,000 Euros ($11,715) in December 2021 and 10,000 Euros ($11,715) in September 2022.
+Added: Additionally,
+Added: the University shall hire and train a doctoral student for this project and as such the Company shall pay the University 25,837
+Added: Euros ($30,268 USD).
+Added: In exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 2% of
+Added: net revenues to the University.
+Added: Certification of Principal Executive Officer pursuant to Rule 13a-14a or 15d-14(a) under the Securities Exchange Act of 1934, as amended, and adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Principal Financial and Accounting Officer pursuant to Rule 13a-14a or 15d-14(a) under the Securities Exchange Act of 1934, as amended, and adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of the Principal Executive Officer pursuant to 18 U.S.C.
+Added: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of the Principal Financial and Accounting Officer pursuant to 18 U.S.C.
+Added: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Instance Document.
8 unchanged sentences
BIOPHARMA, INC.
+Added: November 16, 2020
James Nathanielsz
−Removed: Executive Officer (Principal Executive Officer)
+Added: Executive Officer
+Added: Executive Officer)
Carlo Campiciano
−Removed: Financial Officer (Principal Financial Officer and Principal Accounting Officer)
+Added: Financial Officer
+Added: Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.